alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II (GSD-II)
Conditions
Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-Onset), Acid Maltase Deficiency Disease, Glycogenosis 2
Trial Timeline
— → —
NCT ID
NCT00520143About alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA]) is a pre-clinical stage product being developed by Sanofi for Glycogen Storage Disease Type II (GSD-II). The current trial status is completed. This product is registered under clinical trial identifier NCT00520143. Target conditions include Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-Onset), Acid Maltase Deficiency Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00520143 | Pre-clinical | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II (GSD-II)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| avalglucosidase alfa | Sanofi | Phase 3 | 76 |
| Myozyme | Sanofi | Phase 2/3 | 64 |
| Myozyme | Sanofi | Pre-clinical | 22 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2/3 | 64 |
| ALGLUCOSIDASE ALFA (MYOZYME) | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 76 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 51 |
| Alglucosidase alfa | Sanofi | Phase 2 | 51 |
| Avalglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 1/2 | 40 |
| Alglucosidase alfa GZ419829 | Sanofi | Pre-clinical | 22 |
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| Cipaglucosidase alfa + Miglustat | Amicus Therapeutics | Phase 3 | 74 |
| BEAM-301: Single dose of BEAM-301 administered by IV | Beam Therapeutics | Phase 1/2 | 36 |
| Oral prednisolone + Placebo for oral prednisolone | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| UX053 + Antipyretic + H2 Blocker + H1 Blocker | Ultragenyx Pharmaceutical | Phase 1/2 | 36 |
| [6,6-2H2]glucose | Ultragenyx Pharmaceutical | Phase 1/2 | 36 |